{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:32:57Z","timestamp":1782862377252,"version":"3.54.5"},"reference-count":659,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.gastrohep.2025.502629","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:45:17Z","timestamp":1762958717000},"page":"502629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spanish clinical practice guidelines for the diagnosis and management of cholestatic liver diseases in adult and pediatric population: Joint report from AEEH and SEGHNP"],"prefix":"10.1016","volume":"49","author":[{"given":"\u00c1lvaro","family":"D\u00edaz-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Molera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"G\u00f3mez-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Mu\u00f1oz-Bartolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ampuero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Quintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Olveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Morillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Al\u00f3s","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Garc\u00eda-Buey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Rodr\u00edguez-Tajes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Jorquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carlota","family":"Londo\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2025.502629_bib1000","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1010","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL Clinical Practice Guidelines on sclerosing cholangitis","volume":"77","author":"Chazouilleres","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jhep.2024.04.006","article-title":"EASL Clinical Practice Guidelines on genetic cholestatic liver diseases","volume":"81","author":"Verkade","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1020","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","article-title":"Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Miethke","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1025","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1030","unstructured":"Explanation of the 2011 OCEBM Levels of Evidence \u2013 Centre for Evidence-Based Medicine (CEBM), University of Oxford n.d. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/explanation-of-the-2011-ocebm-levels-of-evidence [accessed 17.7.25]."},{"key":"10.1016\/j.gastrohep.2025.502629_bib1035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1040","first-page":"925","article-title":"Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition","volume":"39","author":"Moyer","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MPG.0000000000001334","volume":"64","author":"Fawaz","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1050","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bmj.c2409","article-title":"Neonatal jaundice: summary of NICE guidance","volume":"340","author":"Rennie","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1055","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.pcl.2017.01.006","article-title":"Neonatal cholestasis","volume":"64","author":"Lane","year":"2017","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.dld.2021.09.011","article-title":"Diagnostic approach to neonatal and infantile cholestasis: a position paper by the SIGENP liver disease working group","volume":"54","author":"Ranucci","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1065","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41575-019-0132-z","article-title":"Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics","volume":"16","author":"Feldman","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1070","first-page":"29","article-title":"Recent developments in diagnostics and treatment of neonatal cholestasis","author":"Feldman","year":"2020","journal-title":"Semin Pediatr Surg"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1075","doi-asserted-by":"crossref","first-page":"150945","DOI":"10.1016\/j.sempedsurg.2020.150945","article-title":"Recent developments in diagnostics and treatment of neonatal cholestasis","volume":"29","author":"Feldman","year":"2020","journal-title":"Semin Pediatr Surg"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jpeds.2019.04.016","article-title":"Diagnostic yield of an algorithm for neonatal and infantile cholestasis integrating next-generation sequencing","volume":"211","author":"Nicastro","year":"2019","journal-title":"J Pediatr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clinre.2018.07.010","article-title":"Systematic review of progressive familial intrahepatic cholestasis","volume":"43","author":"Baker","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1090","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/MPG.0b013e3181dffe8f","article-title":"Analysis of gene mutations in children with cholestasis of undefined etiology","volume":"51","author":"Matte","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1095","first-page":"11","article-title":"A specially designed multi-gene panel facilitates genetic diagnosis in children with intrahepatic cholestasis: simultaneous test of known large insertions\/deletions","author":"Wang","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jpeds.2016.01.006","article-title":"Molecular genetic dissection and neonatal\/infantile intrahepatic cholestasis using targeted next-generation sequencing","volume":"171","author":"Togawa","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.gtc.2018.07.014","article-title":"Molecular mechanisms in pediatric cholestasis","volume":"47","author":"Squires","year":"2018","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jpeds.2018.05.009","article-title":"Reduced hepatocellular expression of canalicular transport proteins in infants with neonatal cholestasis and congenital hypopituitarism","volume":"200","author":"Grammatikopoulos","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1115","first-page":"11","article-title":"Cholestasis reveals severe cortisol deficiency in neonatal pituitary stalk interruption syndrome","author":"Mauvais","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1120","first-page":"13","article-title":"Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood","author":"Gonzales","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1125","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cld.2018.06.006","article-title":"Inborn errors of bile acid metabolism","volume":"22","author":"Heubi","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1135","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/liv.12690","article-title":"Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis","volume":"35","author":"Norman","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1140","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.14309\/ajg.0000000000000690","article-title":"Novel anti-hexokinase 1 antibodies are associated with poor prognosis in patients with primary biliary cholangitis","volume":"115","author":"Reig","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00535-003-1285-6","article-title":"Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture","volume":"39","author":"Shibata","year":"2004","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1155","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hep.28859","article-title":"Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis","volume":"65","author":"Dahlqvist","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1160","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/hep4.2067","article-title":"The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti-mitochondrial antibodies but without baseline PBC","volume":"6","author":"Duan","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.24630","article-title":"Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis","volume":"55","author":"Lleo","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1170","first-page":"46","article-title":"Non-invasive diagnosis and follow-up of primary biliary cholangitis","author":"Corpechot","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1175","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/jcp.2005.028936","article-title":"Can the laboratory affect the investigation and diagnosis of primary biliary cirrhosis?","volume":"59","author":"Sinclair","year":"2006","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1180","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1185","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1190","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.3748\/wjg.v27.i29.4890","article-title":"Poor performance of anti-mitochondrial antibodies for the diagnosis of primary biliary cholangitis in female Colombian patients: a single-center study","volume":"27","author":"Guatibonza-Garci\u00e1","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1195","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/hep4.1907","article-title":"A neglected serum biomarker in treatment-naive primary biliary cholangitis with normal alkaline phosphatase","volume":"6","author":"Ding","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1200","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/hep4.1907","article-title":"Immunoglobulin M: a neglected serum biomarker in treatment-naive primary biliary cholangitis with normal alkaline phosphatase","volume":"6","author":"Ding","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1205","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaut.2019.01.005","article-title":"Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: is alkaline phosphatase truly a surrogate marker?","volume":"99","author":"Sun","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1215","first-page":"116","article-title":"Primary biliary cholangitis with normal alkaline phosphatase: a neglected clinical entity challenging current guidelines","author":"Terziroli Beretta-Piccoli","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1220","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1159\/000507392","article-title":"How much liver tissue is required for sufficient histological staging in patients with primary biliary cholangitis?","volume":"102","author":"Vetter","year":"2021","journal-title":"Digestion"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/cgh.2003.50014","article-title":"When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?","volume":"1","author":"Zein","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1230","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/jclinpath-2019-205958","article-title":"Liver biopsy in primary biliary cholangitis: is sinusoidal fibrosis the missing key?","volume":"72","author":"Warnes","year":"2019","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1235","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1240","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1080\/00365521.2019.1683226","article-title":"Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis","volume":"54","author":"Abdulkarim","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1245","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1250","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1255","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cgh.2019.08.013","article-title":"Factors associated with progression and outcomes of early stage primary biliary cholangitis","volume":"18","author":"Gatselis","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1260","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/liv.14688","article-title":"Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis","volume":"41","author":"Haldar","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1265","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/jgh.14900","article-title":"IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate","volume":"35","author":"Takano","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1270","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","author":"Trivedi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1275","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1280","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1285","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/hepr.12861","article-title":"Comparison between real-time tissue elastography and vibration-controlled transient elastography for the assessment of liver fibrosis and disease progression in patients with primary biliary cholangitis","volume":"47","author":"Koizumi","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1290","first-page":"14","article-title":"Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease","author":"Park","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1295","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.21037\/qims-21-657","article-title":"Shear wave elastography and shear wave dispersion imaging in primary biliary cholangitis \u2013 a pilot study","volume":"12","author":"Schulz","year":"2022","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1300","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MCG.0000000000001433","article-title":"Liver stiffness measured by either magnetic resonance or transient elastography is associated with liver fibrosis and is an independent predictor of outcomes among patients with primary biliary cholangitis","volume":"55","author":"Osman","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1305","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1315","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1320","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"29","author":"Poupon","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1325","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1053\/gast.1996.v110.pm8613058","article-title":"Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis","volume":"110","author":"Lindor","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1330","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1572-0241.2002.05923.x","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1335","doi-asserted-by":"crossref","first-page":"262","DOI":"10.14309\/ajg.0000000000000512","article-title":"Ursodeoxycholic acid treatment preferentially improves overall survival among african americans with primary biliary cholangitis","volume":"115","author":"Gordon","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1340","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1345","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1055\/s-2005-858281","article-title":"Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis","volume":"43","author":"Leuschner","year":"2005","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1350","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1355","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1360","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1872-034X.2011.00782.x","article-title":"Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis","volume":"41","author":"Azemoto","year":"2011","journal-title":"Hepatol Res"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1365","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/gutjnl-2019-319057","article-title":"Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis","volume":"69","author":"Harms","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1370","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/00365521.2022.2103729","article-title":"Clinical outcomes and sick leave in relation to UDCA treatment in Swedish patients with primary biliary cholangitis","volume":"58","author":"Henriksson","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1375","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1380","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1385","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","article-title":"Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial","volume":"30","author":"Angulo","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1390","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1395","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","article-title":"Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis","volume":"32","author":"Momah","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1400","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1405","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1410","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1415","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/liv.15592","article-title":"Optimizing therapy in primary biliary cholangitis: alkaline phosphatase at six months identifies one-year non-responders and predicts survival","volume":"43","author":"Murillo Perez","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1420","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12072-022-10431-7","article-title":"Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion","volume":"17","author":"Yang","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1425","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1430","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1435","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1016\/S0168-8278(25)00962-6","article-title":"THU-274 efficacy and safety of seladelpar in patients previously treated with fibrates or OCA","volume":"82","author":"Villamil","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1440","unstructured":"Pennington NJ. Zydus therapeutics reports positive topline results from EPICS-III phase 2(b)\/3 trial of saroglitazar magnesium in patients with primary biliary cholangitis, n.d."},{"key":"10.1016\/j.gastrohep.2025.502629_bib1445","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(25)04619-0","article-title":"Combined effect of obeticholic acid and bezafibrate in patients with primary biliary cholangitis and inadequate response or intolerance to ursodeoxycholic acid: 6-month results from a phase 2 trial","volume":"169","author":"Jones","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1450","first-page":"1160","article-title":"Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis","volume":"96","author":"Caballer\u00eda","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1455","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.510260508","article-title":"Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes","volume":"26","author":"Jones","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1460","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1465","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12016-015-8483-x","article-title":"Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis","volume":"48","author":"Rong","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1470","first-page":"1495","article-title":"Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid","volume":"22","author":"Kuiper","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1475","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cgh.2006.09.031","article-title":"Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis","volume":"5","author":"Suzuki","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1480","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.22458","article-title":"Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis","volume":"48","author":"Silveira","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MEG.0b013e3282f16436","article-title":"Malignancies in primary biliary cirrhosis","volume":"20","author":"Piscaglia","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1490","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1495","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1500","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1505","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1510","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5582\/bst.2022.01061","article-title":"The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update","volume":"16","author":"Wen","year":"2022","journal-title":"Biosci Trends"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1515","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1520","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1525","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1530","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1535","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"De Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1540","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41395-018-0265-7","article-title":"Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis","volume":"114","author":"Moctezuma-Velazquez","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1545","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cgh.2007.02.031","article-title":"Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis","volume":"5","author":"Levy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1550","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/gut.2004.040832","article-title":"Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?","volume":"54","author":"Bressler","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1555","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5114\/aoms.2017.65450","article-title":"Prediction of oesophageal varices in patients with primary biliary cirrhosis by non-invasive markers","volume":"13","author":"Gao","year":"2017","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1560","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jhep.2013.04.010","article-title":"A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score","volume":"59","author":"Patanwala","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1565","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/17474124.2021.1884071","article-title":"Two-dimensional shear wave elastography for screening varices in Asian patients with primary biliary cholangitis","volume":"15","author":"Yan","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1570","first-page":"23","article-title":"Noninvasive assessment of portal hypertension in patients with primary biliary cholangitis is affected by severity of cholestasis","author":"Calvaruso","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1575","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00535-021-01839-3","article-title":"Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis","volume":"57","author":"Burghart","year":"2022","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1580","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1007\/s00535-006-1914-y","article-title":"Clinical features of symptomatic primary biliary cirrhosis initially complicated with esophageal varices","volume":"41","author":"Murata","year":"2006","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1585","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/TP.0b013e31827afb3a","article-title":"Evolving frequency and outcomes of liver transplantation based on etiology of liver disease","volume":"95","author":"Singal","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1590","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","article-title":"Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)","volume":"57","author":"Adam","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1595","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.cld.2022.06.014","article-title":"Liver transplantation for primary biliary cholangitis","volume":"26","author":"Martin","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198301063080101","article-title":"The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis","volume":"308","author":"Roll","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1610","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0016-5085(85)90213-6","article-title":"Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial","volume":"89","author":"Christensen","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1615","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10620-019-05786-1","article-title":"Outcomes of liver transplant candidates with primary biliary cholangitis: the data from the scientific registry of transplant recipients","volume":"65","author":"Sayiner","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1620","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S2468-1253(22)00354-5","article-title":"Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study","volume":"8","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198201073060101","article-title":"Recurrence of primary biliary cirrhosis after liver transplantation","volume":"306","author":"Neuberger","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1630","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/jhep.2001.20894","article-title":"Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center","volume":"33","author":"Liermann Garcia","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1635","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2018.10.001","article-title":"Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival","volume":"156","author":"Montano-Loza","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1640","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/jlts.2003.50096","article-title":"Recurrent primary biliary cirrhosis","volume":"9","author":"Neuberger","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1645","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0168-8278(05)80244-2","article-title":"Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation","volume":"18","author":"Hubscher","year":"1993","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib0655","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2020.12.005","article-title":"Risk factors for recurrent primary biliary cirrhosis after liver transplantation: a systematic review and meta-analysis","volume":"53","author":"Li","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib0660","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jhep.2020.03.043","article-title":"Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis","volume":"73","author":"Corpechot","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib0665","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/lt.25935","article-title":"Ursodeoxycholic acid decreases incidence of primary biliary cholangitis and biliary complications after liver transplantation: a meta-analysis","volume":"27","author":"Pedersen","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2025.502629_bib0670","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/jlts.2003.50132","article-title":"The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation","volume":"9","author":"Levitsky","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2025.502629_bib0675","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.transproceed.2005.03.130","article-title":"Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival","volume":"37","author":"Jacob","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib0680","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jceh.2022.07.002","article-title":"Post-transplant immunosuppression in autoimmune liver disease","volume":"13","author":"Kelly","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib0685","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1515\/med-2022-0526","article-title":"Noninvasive diagnosis of AIH\/PBC overlap syndrome based on prediction models","volume":"17","author":"Wang","year":"2022","journal-title":"Open Med (Wars)"},{"key":"10.1016\/j.gastrohep.2025.502629_bib0690","first-page":"13","article-title":"Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS)","author":"Nguyen","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2025.502629_bib0695","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib0700","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0399-8320(07)89323-7","article-title":"Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease","volume":"31","author":"Heurgu\u00e9","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1700","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1746.2004.03372.x","article-title":"Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome","volume":"19","author":"Suzuki","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1705","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/MEG.0000000000000075","article-title":"Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis","volume":"26","author":"Efe","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1710","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1478-3231.2007.01538.x","article-title":"Development of autoimmune hepatitis in primary biliary cirrhosis","volume":"27","author":"Gossard","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1715","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","article-title":"Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis","volume":"44","author":"Poupon","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1720","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ajg.2009.616","article-title":"Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis","volume":"105","author":"Neuhauser","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1725","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1572-0241.2002.05703.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system","volume":"97","author":"Talwalkar","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1730","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1735","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cgh.2010.03.004","article-title":"Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome","volume":"8","author":"Kuiper","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1740","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1745","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cgh.2011.03.019","article-title":"Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"9","author":"Bonder","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1750","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/hep4.1148","article-title":"New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome","volume":"2","author":"Zhang","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1755","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: international autoimmune hepatitis group","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1760","first-page":"6","article-title":"Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy","author":"Stoelinga","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1765","first-page":"139","article-title":"Lysophosphatidic acid is a potential mediator of cholestatic pruritus","author":"Kremer","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1770","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1055\/s-0041-1730923","article-title":"MRGPRX4 in cholestatic pruritus","volume":"41","author":"Yu","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1775","first-page":"26","article-title":"Pruritus in chronic cholestatic liver diseases, especially in primary biliary cholangitis: a narrative review","author":"Kanda","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1780","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1785","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1136\/gut.2005.065862","article-title":"Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis","volume":"54","author":"Jacoby","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1790","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1795","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1800","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus","volume":"102","author":"Tandon","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1805","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study","volume":"37","author":"Terg","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1810","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1815","article-title":"Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","author":"Hirschfield","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1820","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1001\/jama.285.17.2196","article-title":"Grip strength and subjective fatigue in patients with primary biliary cirrhosis","volume":"285","author":"Goldblatt","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1825","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cgh.2008.04.013","article-title":"Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis","volume":"6","author":"Hollingsworth","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1830","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4254\/wjh.v14.i6.1111","article-title":"Understanding fatigue in primary biliary cholangitis: from pathophysiology to treatment perspectives","volume":"14","author":"Lynch","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1835","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.1038\/ctg.2017.34","article-title":"Primary biliary cholangitis alters functional connections of the brain's deep gray matter","volume":"8","author":"Mosher","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1840","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jhep.2010.05.036","article-title":"Central nervous system dysfunction in primary biliary cirrhosis and its relationship to symptoms","volume":"53","author":"McDonald","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1845","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MJT.0000000000000387","article-title":"A randomized, placebo-controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis","volume":"24","author":"Silveira","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1850","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s10620-006-9397-5","article-title":"Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial","volume":"51","author":"Talwalkar","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1855","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2036.2003.01398.x","article-title":"Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial","volume":"17","author":"Prince","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1860","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/liv.15596","article-title":"Setanaxib, a first-in-class selective NADPH oxidase 1\/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial","volume":"43","author":"Invernizzi","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1865","doi-asserted-by":"crossref","first-page":"101210","DOI":"10.1016\/j.jhepr.2024.101210","article-title":"A home-based exercise programme attenuates fatigue in primary biliary cholangitis: results from the EXCITED clinical trial","volume":"6","author":"Freer","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1870","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0040-1722264","article-title":"Intrahepatic cholestasis of pregnancy: natural history and current management","volume":"41","author":"Roediger","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1875","first-page":"100","article-title":"Ursodeoxycholic acid improves pregnancy outcome in patients with intrahepatic cholestasis during pregnancy: a protocol for systematic review and meta-analysis","author":"Wang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1880","first-page":"752","article-title":"Efficacy and safety of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy","volume":"15","author":"Par\u00edzek","year":"2016","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1885","first-page":"12","article-title":"Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis","author":"Trivedi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1890","first-page":"14","article-title":"Hepatoprotective agents in the management of intrahepatic cholestasis of pregnancy: current knowledge and prospects","author":"Shan","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1895","first-page":"14","article-title":"Feto-maternal effects of adding rifampicin to ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy","author":"Kumari","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1900","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1600-0773.1989.tb00648.x","article-title":"Teratological study of the hypolipidaemic drugs etofylline clofibrate (VULM) and fenofibrate in Swiss mice","volume":"64","author":"Ujh\u00e1zy","year":"1989","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1905","unstructured":"Ficha T\u00e9cnica n.d.Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. FT 55728: ficha t\u00e9cnica del medicamento [Internet]. [place of publication unknown]: AEMPS; [cited 2025 Nov 27]. Available at: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/55728\/FT_55728.html.pdf"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1910","first-page":"e99","article-title":"Severe hypertriglyceridemia in pregnancy: a case report and review of the literature","volume":"5","author":"Kleess","year":"2018","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1915","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/AOG.0b013e31820755b5","article-title":"Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate","volume":"117","author":"Whitten","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1920","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/j.jhep.2023.04.014","article-title":"Use of fenofibrate for intrahepatic cholestasis of pregnancy","volume":"79","author":"Grady","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1925","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.hbpd.2022.03.005","article-title":"Primary biliary cholangitis in pregnancy: a systematic review with meta-analysis","volume":"21","author":"El Jamaly","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1930","first-page":"11","article-title":"Cholestatic liver disease and pregnancy: a systematic review and meta-analysis","author":"Ferrigno","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1935","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/1471-0528.16119","article-title":"Pregnancy outcomes in women with primary biliary cholangitis and primary sclerosing cholangitis: a retrospective cohort study","volume":"127","author":"Cauldwell","year":"2020","journal-title":"BJOG"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1940","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/liv.13591","article-title":"Complications, symptoms, quality of life and pregnancy in cholestatic liver disease","volume":"38","author":"Zakharia","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1945","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis \u2013 a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1950","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1955","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1960","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1965","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.29293","article-title":"Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group","volume":"66","author":"Schramm","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1970","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1148\/radiol.10091953","article-title":"Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography","volume":"256","author":"Dave","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1975","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/liv.12640","article-title":"Primary sclerosing cholangitis increases the risk for pancreatitis after endoscopic retrograde cholangiopancreatography","volume":"35","author":"von Seth","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1980","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2021.07.046","article-title":"Defining primary sclerosing cholangitis: results from an international primary sclerosing cholangitis study group consensus process","volume":"161","author":"Ponsioen","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1985","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2559.2011.03853.x","article-title":"Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation","volume":"60","author":"Portmann","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1990","first-page":"80","article-title":"European Guideline on IgG4-related digestive disease \u2013 UEG and SGF evidence-based recommendations","volume":"8","author":"L\u00f6hr","year":"2020","journal-title":"Unit Eur Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2025.502629_bib1995","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","article-title":"Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy","volume":"134","author":"Ghazale","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2000","first-page":"3","article-title":"Blue-collar work is a risk factor for developing IgG4-related disease of the biliary tract and pancreas","author":"Hubers","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep4.1467","article-title":"Primary sclerosing cholangitis with features of autoimmune hepatitis: exploring the global variation in management","volume":"4","author":"Milkiewicz","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2010","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2015","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/jcp.48.10.933","article-title":"Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis","volume":"48","author":"Olsson","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2020","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4254\/wjh.v15.i9.1013","article-title":"Noninvasive prognostic models, imaging, and elastography to predict clinical events in primary sclerosing cholangitis: a review","volume":"15","author":"Russo","year":"2023","journal-title":"World J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2025","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/apt.12979","article-title":"Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis","volume":"40","author":"Rupp","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2030","first-page":"246","article-title":"Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis","volume":"15","author":"Hilscher","year":"2016","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2040","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.13110","article-title":"Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value","volume":"36","author":"de Vries","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2050","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/gut.38.4.610","article-title":"Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis","volume":"38","author":"Broom\u00e9","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study","volume":"102","author":"Tischendorf","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2060","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis","volume":"62","author":"Vesterhus","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2065","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2070","first-page":"49","article-title":"Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis","author":"Saffioti","year":"2019","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2075","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A revised natural history model for primary sclerosing cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2080","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2085","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.26620","article-title":"Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression","volume":"59","author":"Ruiz","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2090","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.cgh.2019.03.013","article-title":"Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Lemoinne","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2095","first-page":"142","article-title":"Assessment of prognostic value and interreader agreement of ANALI scores in patients with primary sclerosing cholangitis","author":"Grigoriadis","year":"2021","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.dld.2022.10.015","article-title":"A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis","volume":"55","author":"Cristoferi","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2105","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/hep4.1860","article-title":"A quantitative magnetic resonance cholangiopancreatography metric of intrahepatic biliary dilatation severity detects high-risk primary sclerosing cholangitis","volume":"6","author":"Selvaraj","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2110","first-page":"4","article-title":"Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis","author":"Grigoriadis","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2115","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","author":"Corpechot","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2120","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/00365521.2017.1370009","article-title":"Does transient elastography correlate with liver fibrosis in patients with PSC? Laennec score-based analysis of explanted livers","volume":"52","author":"Krawczyk","year":"2017","journal-title":"Scand J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2025.502629_bib2125","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/jgh.13263","article-title":"Performance of magnetic resonance elastography in primary sclerosing cholangitis","volume":"31","author":"Eaton","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2130","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/hep.22577","article-title":"Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis","volume":"48","author":"Millonig","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2135","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000315","article-title":"Circulating macrophage activation markers predict transplant-free survival in patients with primary sclerosing cholangitis","volume":"12","author":"Bossen","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2140","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2017.01.019","article-title":"Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis","volume":"66","author":"Vesterhus","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2145","first-page":"9","article-title":"Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis","author":"Dhillon","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2150","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hep.31652","article-title":"Bile acid profiles in primary sclerosing cholangitis and their ability to predict hepatic decompensation","volume":"74","author":"Mousa","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2155","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.gie.2009.10.041","article-title":"Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment","volume":"71","author":"Gotthardt","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0168-8278(01)00251-3","article-title":"Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment","volume":"36","author":"Stiehl","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2165","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00330-021-08147-7","article-title":"Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group","volume":"32","author":"Venkatesh","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2170","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.02.013","article-title":"Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline","volume":"66","author":"Aabakken","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cld.2021.08.006","article-title":"Role of endoscopic retrograde cholangiopancreatography in the diagnosis and management of cholestatic liver diseases","volume":"26","author":"Keihanian","year":"2021","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2180","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJM200102083440604","article-title":"Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct","volume":"344","author":"Hammel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2185","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/17474124.2018.1483719","article-title":"Endoscopic management of primary sclerosing cholangitis","volume":"12","author":"Tabibian","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2190","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1136\/gutjnl-2018-316801","article-title":"Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis","volume":"68","author":"Rupp","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2195","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/MEG.0b013e3283554bbf","article-title":"Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience","volume":"24","author":"Chapman","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2200","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.gie.2013.09.015","article-title":"Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"79","author":"Trikudanathan","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2205","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.22441","article-title":"Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis","volume":"48","author":"Charatcharoenwitthaya","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2210","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jhep.2006.05.010","article-title":"Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis","volume":"45","author":"Boberg","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2215","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ajg.2008.161","article-title":"Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis","volume":"104","author":"Bangarulingam","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2220","first-page":"79","article-title":"Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis","author":"Navaneethan","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2225","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gutjnl-2018-317817","article-title":"Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures","volume":"69","author":"Singhi","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2230","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/apt.13817","article-title":"Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis","volume":"44","author":"Njei","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2235","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1055\/s-0034-1391845","article-title":"Prospective evaluation of the clinical utility of single-operator peroral cholangioscopy in patients with primary sclerosing cholangitis","volume":"47","author":"Arnelo","year":"2015","journal-title":"Endoscopy"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2240","first-page":"79","article-title":"Cholangioscopy with narrow-band imaging in patients with primary sclerosing cholangitis undergoing ERCP","author":"Azeem","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2245","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.gie.2021.03.027","article-title":"Probe-based confocal laser endomicroscopy in the evaluation of dominant strictures in patients with primary sclerosing cholangitis: results of a U.S. multicenter prospective trial","volume":"94","author":"Han","year":"2021","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2250","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3748\/wjg.v21.i6.1956","article-title":"Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis","volume":"21","author":"De Vries","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2255","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","article-title":"PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis","volume":"54","author":"Loftus","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2260","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ibd.21699","article-title":"Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients","volume":"18","author":"J\u00f8rgensen","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2265","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1053\/j.gastro.2020.12.036","article-title":"Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis","volume":"160","author":"Wijnands","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2270","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2468-1253(20)30005-4","article-title":"Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study","volume":"5","author":"Ol\u00e9n","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MEG.0000000000000576","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies","volume":"28","author":"Zheng","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2280","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/gut.38.2.234","article-title":"Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis","volume":"38","author":"Penna","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2285","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/0016-5085(86)90926-1","article-title":"Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis","volume":"90","author":"Wiesner","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2290","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cgh.2018.01.020","article-title":"Symptoms do not correlate with findings from colonoscopy in children with inflammatory bowel disease and primary sclerosing cholangitis","volume":"16","author":"Ricciuto","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2295","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/flgastro-2021-102053","article-title":"Faecal calprotectin is a surrogate marker of biliary inflammation in primary sclerosing cholangitis associated inflammatory bowel disease","volume":"13","author":"Pavlidis","year":"2022","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2300","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.ebiom.2015.08.041","article-title":"Contrasting pattern of chronic inflammatory bowel disease in primary and autoimmune sclerosing cholangitis","volume":"2","author":"Bjarnason","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2305","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2310","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1007\/s10620-006-9681-4","article-title":"Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"52","author":"Fevery","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2315","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1572-0241.2004.04067.x","article-title":"Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis","volume":"99","author":"Burak","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2320","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2325","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ajg.2016.55","article-title":"Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD","volume":"111","author":"Gulamhusein","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2330","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.29730","article-title":"Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis","volume":"67","author":"Ali","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2335","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/hep.31575","article-title":"Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis","volume":"73","author":"Eaton","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2340","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/hep.510280316","article-title":"Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography","volume":"28","author":"Keiding","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2345","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jhep.2005.03.016","article-title":"Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"43","author":"Fevery","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2350","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2014.07.032","article-title":"Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET","volume":"61","author":"Sangfelt","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2355","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00268-017-4192-3","article-title":"Diagnostic and prognostic role of 18-FDG PET\/CT in the management of resectable biliary tract cancer","volume":"42","author":"Ma","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2360","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/apt.15146","article-title":"Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis","volume":"49","author":"Wannhoff","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2365","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2013.08.005","article-title":"FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"59","author":"Wannhoff","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2370","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s10620-012-2401-3","article-title":"Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma","volume":"58","author":"Venkatesh","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2375","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cgh.2015.07.014","article-title":"Inflammation but not biliary obstruction is associated with carbohydrate antigen 19-9 levels in patients with primary sclerosing cholangitis","volume":"13","author":"Wannhoff","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2380","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.24570","article-title":"Cancer surveillance in patients with primary sclerosing cholangitis","volume":"54","author":"Razumilava","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2385","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/liv.14326","article-title":"Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps","volume":"40","author":"van Erp","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2390","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ajg.2011.361","article-title":"Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis","volume":"107","author":"Eaton","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2395","first-page":"8","article-title":"Transabdominal ultrasound and endoscopic ultrasound for diagnosis of gallbladder polyps","author":"Wennmacker","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2400","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.cgh.2014.02.008","article-title":"Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis","volume":"12","author":"Zenouzi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2405","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2410","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/00365521.2019.1707277","article-title":"Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland","volume":"55","author":"Barner-Rasmussen","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2415","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis","volume":"36","author":"Bergquist","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2420","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.crohns.2013.02.002","article-title":"Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis","volume":"7","author":"Venkatesh","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2425","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/00365521.2012.685754","article-title":"Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study","volume":"47","author":"Jorgensen","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2430","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.cgh.2020.04.055","article-title":"Colorectal dysplasia and cancer in pediatric-onset ulcerative colitis associated with primary sclerosing cholangitis","volume":"19","author":"El-Matary","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2435","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/ecco-jcc\/jjz066","article-title":"High adherence to surveillance guidelines in inflammatory bowel disease patients results in low colorectal cancer and dysplasia rates, while rates of dysplasia are low before the suggested onset of surveillance","volume":"13","author":"Singh","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2440","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2445","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jhbp.515","article-title":"Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos)","volume":"25","author":"Yokoe","year":"2018","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2450","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1572-0241.2007.01103.x","article-title":"The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis","volume":"102","author":"Kaplan","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2455","first-page":"1504","article-title":"Bile duct bacterial isolates in primary cholangitis and certain other forms of cholestasis \u2013 a study of bile cultures from ERCP","volume":"47","author":"Bjornsson","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2460","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00042737-200601000-00012","article-title":"The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis","volume":"18","author":"Pohl","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2465","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/00365529409103625","article-title":"Etiology and pathogenesis in primary sclerosing cholangitis","volume":"204","author":"Boberg","year":"1994","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2470","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.gie.2014.06.030","article-title":"ERCP-related adverse events in patients with primary sclerosing cholangitis","volume":"81","author":"Navaneethan","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2475","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2018.05.034","article-title":"No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis","volume":"155","author":"Ponsioen","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2480","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.gie.2014.08.008","article-title":"Antibiotic prophylaxis for GI endoscopy","volume":"81","author":"Khashab","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2485","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2006.07.022","article-title":"Biliary candida infections in primary sclerosing cholangitis","volume":"45","author":"Kulaksiz","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2490","first-page":"14","article-title":"Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis","author":"Rupp","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2495","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/apt.12663","article-title":"Fut2 genotype is a risk factor for dominant stenosis and biliary candida infections in primary sclerosing cholangitis","volume":"39","author":"Rupp","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2500","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jhbp.518","article-title":"Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis","volume":"25","author":"Gomi","year":"2018","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2505","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/jhbp.496","article-title":"Indications and techniques of biliary drainage for acute cholangitis in updated Tokyo Guidelines 2018","volume":"24","author":"Mukai","year":"2017","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2510","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/jhbp.519","article-title":"Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis","volume":"25","author":"Mayumi","year":"2018","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2515","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL Clinical Practice Guidelines: liver transplantation","volume":"64","author":"Burra","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2520","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13358","article-title":"2018 Annual Report of the European Liver Transplant Registry (ELTR) \u2013 50-year evolution of liver transplantation","volume":"31","author":"Adam","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2525","first-page":"1267","article-title":"Current therapeutics in primary sclerosing cholangitis","volume":"11","author":"Tan","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2530","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s00535-022-01914-3","article-title":"Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis","volume":"57","author":"Arizumi","year":"2022","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2535","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ajg.2012.06.011","article-title":"Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review","volume":"13","author":"Othman","year":"2012","journal-title":"Arab J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2540","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003626","article-title":"Bile acids for primary sclerosing cholangitis","author":"Chen","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2545","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2550","doi-asserted-by":"crossref","first-page":"26757","DOI":"10.18632\/oncotarget.5610","article-title":"A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis","volume":"6","author":"Zhu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2555","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.27074","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis","volume":"60","author":"Wunsch","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2560","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/hep.22969","article-title":"Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis","volume":"49","author":"Glaser","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2565","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0168-8278(25)00310-1","article-title":"LBO-001 Norucholic acid for the treatment of primary sclerosing cholangitis: 96-week analysis of a pivotal phase 3 trial","volume":"82","author":"Trauner","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2570","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(25)00404-0","article-title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: the ELMWOOD phase II randomized-controlled trial","author":"Levy","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2575","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/j.1572-0241.1999.01156.x","article-title":"The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis","volume":"94","author":"Shetty","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2580","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0016-5085(93)90846-5","article-title":"Increased serum deoxycholic acid levels in men with colorectal adenomas","volume":"104","author":"Bayerd\u00f6rffer","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2585","first-page":"5071","article-title":"Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid","volume":"54","author":"Earnest","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2590","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1349-7006.1998.tb00489.x","article-title":"Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats","volume":"89","author":"Narisawa","year":"1998","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2595","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s10620-013-2772-0","article-title":"Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis","volume":"58","author":"Hansen","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2600","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/MIB.0b013e318286fa61","article-title":"Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis","volume":"19","author":"Singh","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2605","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1053\/j.gastro.2009.12.037","article-title":"AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease","volume":"138","author":"Fa","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2610","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.crohns.2007.12.001","article-title":"European evidence-based consensus on the management of ulcerative colitis: special situations","volume":"2","author":"Biancone","year":"2008","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2615","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jhep.2004.01.002","article-title":"Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy","volume":"40","author":"Brands\u00e6ter","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2620","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/MEG.0b013e328331c2b7","article-title":"Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study","volume":"22","author":"Garioud","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2625","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2013.06.052","article-title":"Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management","volume":"145","author":"Eaton","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2630","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2635","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000471874","article-title":"Immunosuppressive agents for the treatment of primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"35","author":"Peng","year":"2017","journal-title":"Dig Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2640","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/apt.14829","article-title":"Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease","volume":"48","author":"Tse","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2645","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MCG.0b013e3181662426","article-title":"A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis","volume":"42","author":"Hommes","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2650","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11901-019-00456-2","article-title":"The use of biologics in patients with inflammatory bowel disease and primary sclerosing cholangitis","volume":"18","author":"Lynch","year":"2019","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2655","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2660","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2665","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/ibd\/izaa317","article-title":"Association of anti-TNF therapy with increased risk of acute cholangitis in patients with primary sclerosing cholangitis","volume":"27","author":"Kulkarni","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2670","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0016-5085(88)90255-7","article-title":"Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits","volume":"94","author":"Kono","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2675","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/gutjnl-2016-312137","article-title":"Primary sclerosing cholangitis: 50 years of a gut-liver relationship and still no love?","volume":"65","author":"Karlsen","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2680","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1172\/JCI115996","article-title":"Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth","volume":"90","author":"Lichtman","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2685","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/0016-5085(88)90560-4","article-title":"Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis","volume":"94","author":"Hobson","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2690","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2050640617708953","article-title":"The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease","volume":"6","author":"Torres","year":"2018","journal-title":"Unit Eur Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2695","first-page":"178","article-title":"The intestinal microbiome in human health and disease","volume":"131","author":"Dupont","year":"2020","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2700","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/1751-2980.12788","article-title":"Precision medicine in primary sclerosing cholangitis","volume":"20","author":"Maurice","year":"2019","journal-title":"J Dig Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00365521.2020.1787501","article-title":"Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis","volume":"55","author":"Ali","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2710","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis \u2013 a pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2715","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2720","first-page":"2017","article-title":"Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation","author":"Hey","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2725","first-page":"19","article-title":"Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host\u2013microbiome\u2013metabolomic signatures","author":"Quraishi","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2730","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/MJT.0000000000000102","article-title":"Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis","volume":"24","author":"Tabibian","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2735","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ajg.2008.14","article-title":"Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study","volume":"104","author":"Silveira","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2740","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2745","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/HEP.0000000000000278","article-title":"Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC","volume":"78","author":"Sharpton","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2750","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","article-title":"Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2755","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.3748\/wjg.v28.i44.6213","article-title":"Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value","volume":"28","author":"Li","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2760","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1619","article-title":"Efficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis: PERSEUS study","volume":"5","author":"Eksteen","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2765","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2770","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2775","first-page":"36","article-title":"Liver transplantation for primary sclerosing cholangitis (PSC) with or without inflammatory bowel disease (IBD) \u2013 a European Society of Organ Transplantation (ESOT) Consensus Statement","author":"Carbone","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2780","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1600-0676.2000.020002097.x","article-title":"Liver transplantation for primary sclerosing cholangitis","volume":"20","author":"Gow","year":"2000","journal-title":"Liver"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2785","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1097\/TP.0000000000003542","article-title":"Characteristics, trends, and outcomes of liver transplantation for primary sclerosing cholangitis in female versus male patients: an analysis from the European Liver Transplant Registry","volume":"105","author":"Berenguer","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2790","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0037-1608655","article-title":"Timing, management, and outcomes of liver transplantation in primary sclerosing cholangitis","volume":"37","author":"Martin","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2795","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/00365521.2015.1036359","article-title":"Liver transplantation in the Nordic countries \u2013 an intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982\u20132013","volume":"50","author":"Fosby","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2800","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1080\/00365520310006009","article-title":"Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries","volume":"38","author":"Brands\u00e6ter","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2805","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.13894","article-title":"Systematic review: recurrent autoimmune liver diseases after liver transplantation","volume":"45","author":"Montano-Loza","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2810","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jhep.2015.07.005","article-title":"Risk factors for recurrent primary sclerosing cholangitis after liver transplantation","volume":"63","author":"Ravikumar","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2815","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/tri.13814","article-title":"Disease-specific waitlist outcomes in liver transplantation \u2013 a retrospective study","volume":"34","author":"Nagai","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2820","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/PAS.0b013e3181bc96f9","article-title":"Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma","volume":"34","author":"Lewis","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2825","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/00365521.2017.1385840","article-title":"Optimizing the detection of biliary dysplasia in primary sclerosing cholangitis before liver transplantation","volume":"53","author":"Majeed","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2830","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.3748\/wjg.v23.i33.6147","article-title":"Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis","volume":"23","author":"Boyd","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2835","first-page":"1","article-title":"Indications and outcomes in liver transplantation in patients with primary sclerosing cholangitis in Norway","author":"Andersen","year":"2015","journal-title":"Transplant Direct"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2840","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/liv.13276","article-title":"Value of brush cytology for optimal timing of liver transplantation in primary sclerosing cholangitis","volume":"37","author":"Vannas","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2845","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12113157","article-title":"Selected patients with unresectable perihilar cholangiocarcinoma (pCCA) derive long-term benefit from liver transplantation","volume":"12","author":"Azad","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2850","first-page":"99","article-title":"Risk factors for recurrent autoimmune liver diseases after liver transplantation: a meta-analysis","author":"Chen","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2855","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/lt.24350","article-title":"Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: a retrospective multicenter analysis","volume":"22","author":"Hildebrand","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2860","first-page":"4","article-title":"Inflammatory conditions play a role in recurrence of PSC after liver transplantation: an international multicentre study","author":"Visseren","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2865","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jhep.2023.08.031","article-title":"Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis \u2013 a propensity score-matched intention-to-treat analysis","volume":"80","author":"\u00c5berg","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2870","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1097\/TP.0000000000004209","article-title":"Recipient and center factors associated with immunosuppression practice beyond the first year after liver transplantation and impact on outcomes","volume":"106","author":"Bittermann","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2875","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/lt.25838","article-title":"Impact of preexisting inflammatory bowel disease on the outcome of liver transplantation for primary sclerosing cholangitis","volume":"26","author":"Irl\u00e8s-Dep\u00e9","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2880","first-page":"11","article-title":"Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant","author":"Muduma","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2885","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/17474124.2017.1343666","article-title":"Interactions between primary sclerosing cholangitis and inflammatory bowel disease: implications in the adult liver transplant setting","volume":"11","author":"Liu","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2890","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/ajg.2013.163","article-title":"Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2895","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/ibd\/izx096","article-title":"Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis","volume":"24","author":"Loftus","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2900","first-page":"949","article-title":"Safety of combination biologic and antirejection therapy post-liver transplantation in patients with inflammatory bowel disease","volume":"26","author":"Al Draiweesh","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2905","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1478-3231.2011.02677.x","article-title":"The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis","volume":"33","author":"Joshi","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2910","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.transproceed.2013.01.066","article-title":"choledochojejunostomy versus duct-to-duct biliary anastomosis in liver transplantation for primary sclerosing cholangitis: a meta-analysis","volume":"45","author":"Wells","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2915","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/lt.23827","article-title":"Duct-to-duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy","volume":"20","author":"Sutton","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2920","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1600-0676.1996.tb00754.x","article-title":"Pregnancy in patients with primary sclerosing cholangitis","volume":"16","author":"Janczewska","year":"1996","journal-title":"Liver"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2925","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group","volume":"156","author":"Mahadevan","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2930","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/gut.2010.228924","article-title":"Pregnancy in primary sclerosing cholangitis","volume":"60","author":"Wellge","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2935","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00117-023-01207-7","article-title":"Safety of magnetic resonance imaging in pregnancy","volume":"63","author":"Maralani","year":"2023","journal-title":"Radiologie"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2940","doi-asserted-by":"crossref","unstructured":"Smith I, Gaidhane M, Goode A, Kahaleh M. Safety of endoscopic retrograde cholangiopancreatography in pregnancy: fluoroscopy time and fetal exposure, does it matter? World J Gastrointest Endosc 2013;5:148. https:\/\/doi.org\/10.4253\/WJGE.V5.I4.148.","DOI":"10.4253\/wjge.v5.i4.148"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2945","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.dld.2021.08.015","article-title":"Outcome of pregnancy in patients with primary sclerosing cholangitis","volume":"54","author":"Wronka","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2950","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2013.07.011","article-title":"A population-based cohort study of pregnancy outcomes among women with primary sclerosing cholangitis","volume":"12","author":"Ludvigsson","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2955","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2960","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2965","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/MPG.0000000000000245","article-title":"Autoantibody and human leukocyte antigen profiles in children with autoimmune liver disease and their first-degree relatives","volume":"58","author":"Wang","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2970","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2001.22131","article-title":"Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study","volume":"33","author":"Gregorio","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2975","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpeds.2021.07.047","article-title":"Sclerosing cholangitis in pediatric inflammatory bowel disease: early diagnosis and management affect clinical outcome","volume":"238","author":"Hensel","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2980","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jcla.21813","article-title":"Autoantibody profiling in a cohort of pediatric and adult patients with autoimmune hepatitis","volume":"30","author":"Villalta","year":"2016","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2985","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.26454","article-title":"Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history","volume":"58","author":"Deneau","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2990","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.29204","article-title":"The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration","volume":"66","author":"Deneau","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib2995","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/15513815.2014.898721","article-title":"Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents","volume":"33","author":"Rojas","year":"2014","journal-title":"Fetal Pediatr Pathol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3000","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/MPG.0b013e31828b1dfa","article-title":"Celiac disease-associated autoimmune hepatitis in childhood: long-term response to treatment","volume":"56","author":"Nastasio","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jceh.2018.10.006","article-title":"Accuracy of the simplified criteria for autoimmune hepatitis in children: systematic review and decision analysis","volume":"9","author":"Arcos-Machancoses","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3010","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3015","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2001.22131","article-title":"Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study","volume":"33","author":"Gregorio","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/MPG.0000000000001125","article-title":"Clinical characteristics and prognosis in children and adolescents with autoimmune hepatitis and overlap syndrome","volume":"63","author":"Rodrigues","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3025","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.26454","article-title":"Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history","volume":"58","author":"Deneau","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3030","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s10024-005-0020-0","article-title":"Primary sclerosing cholangitis in children: a histologic follow-up study","volume":"8","author":"Batres","year":"2005","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5223\/pghn.2021.24.2.154","article-title":"Autoimmune sclerosing cholangitis in children: a prospective case\u2013control study","volume":"24","author":"Kumar","year":"2021","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/15513815.2014.898721","article-title":"Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents","volume":"33","author":"Rojas","year":"2014","journal-title":"Fetal Pediatr Pathol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3045","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12072-019-09948-1","article-title":"Biliary features in liver histology of children with autoimmune liver disease","volume":"13","author":"Di Giorgio","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3050","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/PAP.0b013e31825c6a20","article-title":"Liver biopsy in modern clinical practice: a pediatric point-of-view","volume":"19","author":"Ovchinsky","year":"2012","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3055","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jceh.2018.10.006","article-title":"Accuracy of the simplified criteria for autoimmune hepatitis in children: systematic review and decision analysis","volume":"9","author":"Arcos-Machancoses","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2008.03722.x","article-title":"Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival","volume":"28","author":"Al-Chalabi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl.2","key":"10.1016\/j.gastrohep.2025.502629_bib3070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000440747","article-title":"Role of histopathology in autoimmune hepatitis","volume":"33","author":"Tiniakos","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3075","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2015.06.008","article-title":"Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis","volume":"63","author":"De Vries","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.dld.2018.07.033","article-title":"Pediatric autoimmune liver disease and extra-hepatic immune-mediated comorbidities","volume":"51","author":"Paolella","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2013.08.004","article-title":"Autoimmune hepatitis: contrasts and comparisons in children and adults \u2013 a comprehensive review","volume":"46","author":"Floreani","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3095","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/MPG.0b013e31828dc5c5","article-title":"Pediatric celiac disease, cryptogenic hypertransaminasemia, and autoimmune hepatitis","volume":"56","author":"Vajro","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"Suppl. 2","key":"10.1016\/j.gastrohep.2025.502629_bib3100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000440707","article-title":"Association of extrahepatic manifestations with autoimmune hepatitis","volume":"33","author":"Wong","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3105","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/MPG.0b013e31828b1dfa","article-title":"Celiac disease-associated autoimmune hepatitis in childhood: long-term response to treatment","volume":"56","author":"Nastasio","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3110","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MPG.0000000000001368","article-title":"The natural history of primary sclerosing cholangitis in children: a large single-center longitudinal cohort study","volume":"63","author":"Valentino","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.29204","article-title":"The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration","volume":"66","author":"Deneau","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3120","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1097\/PG9.0000000000000220","article-title":"Long-term follow-up into adulthood of pediatric-onset primary sclerosing cholangitis and autoimmune sclerosing cholangitis","volume":"3","author":"Hercun","year":"2022","journal-title":"JPGN Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3125","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MPG.0000000000001531","article-title":"Unique inflammatory bowel disease phenotype of pediatric primary sclerosing cholangitis: a single-center study","volume":"65","author":"Shiau","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3130","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.26454","article-title":"Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history","volume":"58","author":"Deneau","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpeds.2021.07.047","article-title":"Sclerosing cholangitis in pediatric inflammatory bowel disease: early diagnosis and management affect clinical outcome","volume":"238","author":"Hensel","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3140","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/ajg.2013.131","article-title":"The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis","volume":"109","author":"Henderson","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3145","first-page":"20","article-title":"and PSC phenotypes of PSC-IBD","author":"Ricciuto","year":"2018","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3150","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cgh.2018.01.020","article-title":"Symptoms do not correlate with findings from colonoscopy in children with inflammatory bowel disease and primary sclerosing cholangitis","volume":"16","author":"Ricciuto","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3155","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.cgh.2019.08.048","article-title":"Primary sclerosing cholangitis in children with inflammatory bowel diseases is associated with milder clinical activity but more frequent subclinical inflammation and growth impairment","volume":"18","author":"Ricciuto","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3160","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/jhep.2002.31872","article-title":"Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis","volume":"35","author":"Boberg","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3165","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A novel prognostic model for transplant-free survival in primary sclerosing cholangitis","volume":"67","author":"De Vries","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3170","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A revised natural history model for primary sclerosing cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3175","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1097\/MPG.0000000000002522","article-title":"Assessing the validity of adult-derived prognostic models for primary sclerosing cholangitis outcomes in children","volume":"70","author":"Deneau","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3180","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.29204","volume":"66","author":"Deneau","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3185","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MPG.0000000000001368","article-title":"The natural history of primary sclerosing cholangitis in children: a large single-center longitudinal cohort study","volume":"63","author":"Valentino","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3190","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1572-0241.2004.04106.x","article-title":"Dominant strictures in patients with primary sclerosing cholangitis","volume":"99","author":"Bj\u00f6rnsson","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3195","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/hep.31393","article-title":"The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) index: a prognostic tool for children","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3200","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00261-019-02184-z","article-title":"Differentiating pediatric autoimmune liver diseases by quantitative magnetic resonance cholangiopancreatography","volume":"45","author":"Gilligan","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3205","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00247-018-4319-1","article-title":"Diagnostic performance of quantitative magnetic resonance imaging biomarkers for predicting portal hypertension in children and young adults with autoimmune liver disease","volume":"49","author":"Dillman","year":"2019","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3210","first-page":"11","article-title":"Quantitative multiparametric MRI as a non-invasive stratification tool in children and adolescents with autoimmune liver disease","author":"Janowski","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3215","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","author":"Corpechot","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3220","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1258\/0004563021901685","article-title":"Gamma-glutamyltransferase: value of its measurement in paediatrics","volume":"39","author":"Cabrera-Abreu","year":"2002","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3225","first-page":"6","article-title":"Gamma-glutamyl transferase and disease course in pediatric-onset primary sclerosing cholangitis: a single-center cohort study","author":"Berhane","year":"2023","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3230","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/hep4.1251","article-title":"Gamma glutamyltransferase reduction is associated with favorable outcomes in pediatric primary sclerosing cholangitis","volume":"2","author":"Deneau","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3235","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpeds.2019.01.039","article-title":"Ursodeoxycholic acid therapy in pediatric primary sclerosing cholangitis: predictors of gamma glutamyltransferase normalization and favorable clinical course","volume":"209","author":"Deneau","year":"2019","journal-title":"J Pediatr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3240","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1111\/liv.14159","article-title":"Disease progression in paediatric- and adult-onset sclerosing cholangitis: results from two independent Dutch registries","volume":"39","author":"Joosse","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3245","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1053\/j.gastro.2020.07.066","article-title":"Predicting outcomes in pediatric ulcerative colitis for management optimization: systematic review and consensus statements from the pediatric inflammatory bowel disease-ahead program","volume":"160","author":"Orlanski-Meyer","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3250","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000082893","article-title":"Pediatric inflammatory bowel disease in southeastern Norway: a five-year follow-up study","volume":"70","author":"St\u00f8rdal","year":"2004","journal-title":"Digestion"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3255","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.crohns.2013.12.010","article-title":"Genetic susceptibility and genotype\u2013phenotype association in 588 Danish children with inflammatory bowel disease","volume":"8","author":"Jakobsen","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3260","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/lt.22320","article-title":"Pediatric liver transplantation for primary sclerosing cholangitis","volume":"17","author":"Miloh","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3265","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1097\/MPG.0000000000001438","article-title":"Liver transplantation for children with primary sclerosing cholangitis and autoimmune hepatitis: UNOS database analysis","volume":"64","author":"Jossen","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3270","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/hep.31911","article-title":"Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study","volume":"74","author":"Martinez","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3275","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/apt.14893","article-title":"Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN","volume":"48","author":"Joosse","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3280","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.MIB.0000439066.69340.3c","article-title":"Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric IBD group","volume":"20","author":"De Ridder","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3285","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1053\/j.gastro.2018.10.028","article-title":"Increased mortality of patients with childhood-onset inflammatory bowel diseases, compared with the general population","volume":"156","author":"Ol\u00e9n","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3290","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/hep4.1421","article-title":"A prospective trial of withdrawal and reinstitution of ursodeoxycholic acid in pediatric primary sclerosing cholangitis","volume":"3","author":"Black","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3295","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hep.31560","article-title":"Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3300","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cgh.2008.10.019","article-title":"A retrospective single-center review of primary sclerosing cholangitis in children","volume":"7","author":"Miloh","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3305","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1499-3872(16)60088-7","article-title":"Long-term follow-up of children and adolescents with primary sclerosing cholangitis and autoimmune sclerosing cholangitis","volume":"15","author":"Smolka","year":"2016","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3310","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1097\/MPG.0000000000001438","article-title":"Liver transplantation for children with primary sclerosing cholangitis and autoimmune hepatitis: UNOS database analysis","volume":"64","author":"Jossen","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3315","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"Lohse","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3320","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00247-008-0918-6","article-title":"Primary sclerosing cholangitis in children: utility of magnetic resonance cholangiopancreatography","volume":"38","author":"Chavhan","year":"2008","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3325","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00247-001-0617-z","article-title":"Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children","volume":"32","author":"Ferrara","year":"2002","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3330","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/jmri.27113","article-title":"Quantitative MRCP imaging: accuracy, repeatability, reproducibility, and cohort-derived normative ranges","volume":"52","author":"Goldfinger","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3335","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/hep4.1454","article-title":"Magnetic resonance cholangiopancreatography severity predicts disease outcomes in pediatric primary sclerosing cholangitis: a reliability and validity study","volume":"4","author":"Patil","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3340","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2214\/AJR.21.27204","article-title":"Associations between quantitative MRI metrics and clinical risk scores in children and young adults with autoimmune liver disease","volume":"219","author":"McCrary","year":"2022","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3345","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00261-021-03378-0","article-title":"Associations between MRI T1 mapping, liver stiffness, quantitative MRCP, and laboratory biomarkers in children and young adults with autoimmune liver disease","volume":"47","author":"Mahalingam","year":"2022","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3350","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0022-3476(94)70253-5","article-title":"Sclerosing cholangitis in children","volume":"124","author":"Debray","year":"1994","journal-title":"J Pediatr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3355","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/2050640615616012","article-title":"Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis","volume":"4","author":"Tenca","year":"2016","journal-title":"Unit Eur Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3360","first-page":"1415","article-title":"Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis","volume":"22","author":"Wilschanski","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3365","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/jhep.2003.50289","article-title":"Primary sclerosing cholangitis in children: a long-term follow-up study","volume":"38","author":"Feldstein","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3370","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MCG.0b013e3181662426","article-title":"A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis","volume":"42","author":"Hommes","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3375","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3380","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0168-8278(01)00158-1","article-title":"FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte","volume":"35","author":"Eppens","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3385","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ng0398-219","article-title":"A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis","volume":"18","author":"Bull","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3390","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1053\/jhep.2001.27663","article-title":"Familial intrahepatic cholestasis 1: studies of localization and function","volume":"34","author":"Ujhazy","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3395","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hep.21950","article-title":"ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity","volume":"47","author":"Paulusma","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3400","first-page":"2018","article-title":"New insights in genetic cholestasis: from molecular mechanisms to clinical implications","author":"Sticova","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3405","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1053\/j.gastro.2011.07.042","article-title":"Complementary functions of the flippase ATP8B1 and the floppase ABCB4 in maintaining canalicular membrane integrity","volume":"141","author":"Groen","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3410","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/hep.21212","article-title":"Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport","volume":"44","author":"Paulusma","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3415","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/hmg\/ddh261","article-title":"Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1","volume":"13","author":"Alvarez","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3420","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/hep.22431","article-title":"The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor","volume":"48","author":"Frankenberg","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3425","first-page":"126","article-title":"Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity","author":"Chen","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3430","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31787","article-title":"Impact of genotype, serum bile acids, and surgical biliary diversion on native liver survival in FIC1 deficiency","volume":"74","author":"van Wessel","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3435","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hep.20285","article-title":"Characterization of mutations in ATP8B1 associated with hereditary cholestasis","volume":"40","author":"Klomp","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3440","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpeds.2021.04.040","article-title":"ATP8B1, ABCB11, and ABCB4 genes defects: novel mutations associated with cholestasis with different phenotypes and outcomes","volume":"236","author":"Al-Hussaini","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3445","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/hep.23158","article-title":"Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1","volume":"50","author":"Folmer","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3450","first-page":"12","article-title":"The genetics of inherited cholestatic disorders in neonates and infants: evolving challenges","author":"Jeyaraj","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3455","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hep.20285","article-title":"Characterization of mutations in ATP8B1 associated with hereditary cholestasis","volume":"40","author":"Klomp","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3460","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2313675","article-title":"New insights in genetic cholestasis: from molecular mechanisms to clinical implications","volume":"2018","author":"Sticova","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3465","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31787","article-title":"Impact of genotype, serum bile acids, and surgical biliary diversion on native liver survival in FIC1 deficiency","volume":"74","author":"van Wessel","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3470","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/MPG.0b013e3181cd2725","article-title":"Heterozygous FIC1 deficiency: a new genetic predisposition to transient neonatal cholestasis","volume":"50","author":"Jacquemin","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3475","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jhep.2017.07.004","article-title":"Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants","volume":"67","author":"Dr\u00f6ge","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3480","first-page":"134","article-title":"Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families","author":"Strautnieks","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3485","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/3034","article-title":"A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis","volume":"20","author":"Strautnieks","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3490","first-page":"12","article-title":"The genetics of inherited cholestatic disorders in neonates and infants: evolving challenges","author":"Jeyaraj","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3495","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/hep.23539","article-title":"ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history","volume":"51","author":"Davit-Spraul","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3500","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2010.01.034","article-title":"Differences in presentation and progression between severe FIC1 and BSEP deficiencies","volume":"53","author":"Pawlikowska","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3505","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2020.02.007","article-title":"Genotype correlates with the natural history of severe bile salt export pump deficiency","volume":"73","author":"van Wessel","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3510","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1111\/liv.14642","article-title":"ABCB11 deficiency presenting as transient neonatal cholestasis: correlation with genotypes and BSEP expression","volume":"40","author":"Li","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3515","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/ped.12049","article-title":"Association of variants of ABCB11 with transient neonatal cholestasis","volume":"55","author":"Liu","year":"2013","journal-title":"Pediatr Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3520","first-page":"12","article-title":"The genetics of inherited cholestatic disorders in neonates and infants: evolving challenges","author":"Jeyaraj","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3525","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jhep.2017.07.004","article-title":"Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants","volume":"67","author":"Dr\u00f6ge","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3530","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/gut.2008.159541","article-title":"Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy","volume":"58","author":"Dixon","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3535","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2010.01.034","article-title":"Differences in presentation and progression between severe FIC1 and BSEP deficiencies","volume":"53","author":"Pawlikowska","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3540","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.cld.2010.08.001","article-title":"Trafficking and transporter disorders in pediatric cholestasis","volume":"14","author":"Knisely","year":"2010","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3545","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0016-5085(99)70287-8","article-title":"Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis","volume":"117","author":"Jansen","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3550","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/hep.20682","article-title":"Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis","volume":"41","author":"Keitel","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3555","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.cld.2022.03.011","article-title":"Fat soluble vitamin assessment and supplementation in cholestasis","volume":"26","author":"Kamath","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3560","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jhn.12957","article-title":"Fat-soluble vitamin assessment, deficiency and supplementation in infants with cholestasis","volume":"35","author":"Mancell","year":"2022","journal-title":"J Hum Nutr Diet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3565","doi-asserted-by":"crossref","first-page":"100626","DOI":"10.1016\/j.jhepr.2022.100626","article-title":"Genotype\u2013phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency","volume":"5","author":"Felzen","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3570","first-page":"5","article-title":"Genotype\u2013phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency","author":"Felzen","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3575","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.27834","article-title":"Retargeting of bile salt export pump and favorable outcome in children with progressive familial intrahepatic cholestasis type 2","volume":"62","author":"Varma","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3580","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-3468(98)90435-3","article-title":"Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus","volume":"33","author":"Hollands","year":"1998","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3585","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MPG.0000000000002789","article-title":"Systematic review and meta-analysis: partial external biliary diversion in progressive familial intrahepatic cholestasis","volume":"71","author":"Verkade","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3590","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/17474124.2022.2032660","article-title":"Biliary diversion in progressive familial intrahepatic cholestasis: a systematic review and meta-analysis","volume":"16","author":"Bolia","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3595","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-2003-43570","article-title":"Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass","volume":"13","author":"Kalici\u0144ski","year":"2003","journal-title":"Eur J Pediatr Surg"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3600","first-page":"10","article-title":"Progressive familial intrahepatic cholestasis\u2014outcome and time to transplant after biliary diversion according to genetic subtypes","author":"Sahloul","year":"2023","journal-title":"Front Surg"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3605","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3610","first-page":"5","article-title":"Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis","author":"Thompson","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3615","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1002\/hep4.1980","article-title":"Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, phase 2 study","volume":"6","author":"Loomes","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3620","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jpedsurg.2011.08.010","article-title":"Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis","volume":"47","author":"Schukfeh","year":"2012","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3625","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.95.1.282","article-title":"Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis","volume":"95","author":"De Vree","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3630","unstructured":"Tissue distribution of the human MDR3 P-glycoprotein \u2013 PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/7734012\/ [accessed 8.8.24]."},{"key":"10.1016\/j.gastrohep.2025.502629_bib3635","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1172\/JCI117658","article-title":"Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse","volume":"95","author":"Oude Elferink","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3640","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/0092-8674(94)90446-4","article-title":"Phosphatidylcholine translocase: a physiological role for the mdr2 gene","volume":"77","author":"Ruetz","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3645","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","article-title":"Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease","volume":"75","author":"Smit","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3650","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/hep.510280234","article-title":"Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (\u2212\/\u2212) mice","volume":"28","author":"Smith","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3655","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/hep.20022","article-title":"Spontaneous cholecysto- and hepatolithiasis in Mdr2\u2212\/\u2212 mice: a model for low phospholipid-associated cholelithiasis","volume":"39","author":"Lammert","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3660","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1053\/gast.2001.23984","article-title":"The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood","volume":"120","author":"Jacquemin","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3665","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.28300","article-title":"A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3","volume":"63","author":"Delaunay","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3670","first-page":"5","article-title":"Outcomes of 38 patients with PFIC3: impact of genotype and of response to ursodeoxycholic acid therapy","author":"Gonzales","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3675","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MPG.0b013e3181f50363","article-title":"Clinical features and genotype\u2013phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations","volume":"52","author":"Colombo","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3680","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/liv.12910","article-title":"Heterozygous ABCB4 mutations in children with cholestatic liver disease","volume":"36","author":"Gordo-Gilart","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3685","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jpn3.12080","article-title":"Clinical outcomes of ABCB4 heterozygosity in infants and children with cholestatic liver disease","volume":"78","author":"Hegarty","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3690","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/hep4.1149","article-title":"Phenotypic spectrum and diagnostic pitfalls of ABCB4 deficiency depending on age of onset","volume":"2","author":"Schatz","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3695","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.26424","article-title":"Genotype\u2013phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: a study of 156 consecutive patients","volume":"58","author":"Poupon","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3700","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jviscsurg.2019.02.006","article-title":"Low-Phospholipid Associated Cholelithiasis (LPAC) syndrome: a synthetic review","volume":"156","author":"Goubault","year":"2019","journal-title":"J Visc Surg"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3705","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(05)77221-4","article-title":"Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy","volume":"353","author":"Jacquemin","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3710","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/s-0030-1253223","article-title":"The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects","volume":"30","author":"Davit-Spraul","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3715","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jmg.2009.067397","article-title":"ABCB4 gene mutations and single-nucleotide polymorphisms in women with intrahepatic cholestasis of pregnancy","volume":"46","author":"Bacq","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3720","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.fpc.0000230418.28091.76","article-title":"Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury","volume":"17","author":"Lang","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3725","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jhep.2012.01.025","article-title":"ABCB4\/MDR3 gene mutations and cholangiocarcinomas","volume":"57","author":"Tougeron","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3730","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/gutjnl-2014-306896","article-title":"Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity","volume":"64","author":"Gordo-Gilart","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3735","first-page":"4","author":"Davit-Spraul","year":"2009","journal-title":"Rare Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3740","first-page":"25","article-title":"Progressive familial intrahepatic cholestasis type 3: report of four clinical cases, novel ABCB4 variants and long-term follow-up","author":"Lipi\u0144ski","year":"2021","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3745","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.anndiagpath.2015.06.002","article-title":"Liver pathology in severe multidrug resistant 3 protein deficiency: a series of 10 pediatric cases","volume":"19","author":"Vij","year":"2015","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3750","first-page":"7","article-title":"Real-world experience with odevixibat in children with progressive familial intrahepatic cholestasis","author":"Di Giorgio","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3755","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5500\/wjt.v6.i2.278","article-title":"Liver transplantation and the management of progressive familial intrahepatic cholestasis in children","volume":"6","author":"Mehl","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3760","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.tp.0000282869.94152.4f","article-title":"Liver transplantation in children with progressive familial intrahepatic cholestasis","volume":"84","author":"Englert","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3765","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00268-010-0869-6","article-title":"Living-donor liver transplantation for progressive familial intrahepatic cholestasis","volume":"35","author":"Hori","year":"2011","journal-title":"World J Surg"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3770","first-page":"25","article-title":"Long-term liver transplant outcomes for progressive familial intrahepatic cholestasis type 1: the Pittsburgh experience","author":"Henkel","year":"2021","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3775","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0168-8278(03)00286-1","article-title":"Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation","volume":"39","author":"Lykavieris","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3780","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/lt.21686","article-title":"Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation","volume":"15","author":"Miyahawa-Hayashino","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3785","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPG.0000000000002983","article-title":"Long-term outcomes of living-donor liver transplantation for progressive familial intrahepatic cholestasis type 1","volume":"72","author":"Okamoto","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3790","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1053\/jlts.2002.34384","article-title":"Intractable diarrhea after liver transplantation for Byler's disease: successful treatment with bile adsorptive resin","volume":"8","author":"Egawa","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3795","first-page":"9","article-title":"Internal ileal diversion as treatment for progressive familial intrahepatic cholestasis type 1-associated graft inflammation and steatosis after liver transplantation","author":"Kavallar","year":"2022","journal-title":"Children (Basel)"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3800","first-page":"16","article-title":"Recovery of graft steatosis and protein-losing enteropathy after biliary diversion in a PFIC 1 liver transplanted child","author":"Nicastro","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3805","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/petr.12782","article-title":"Total internal biliary diversion during liver transplantation for type 1 progressive familial intrahepatic cholestasis: a novel approach","volume":"20","author":"Mali","year":"2016","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3810","first-page":"27","article-title":"Outcomes of pediatric liver transplantation for progressive familial intrahepatic cholestasis","author":"Vasudevan","year":"2023","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3815","first-page":"9","article-title":"Ileal bile acid transporter inhibition reduces post-transplant diarrhea and growth failure in FIC1 disease \u2013 a case report","author":"Ohlendorf","year":"2022","journal-title":"Children (Basel)"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3820","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa0901075","article-title":"Recurrence of bile salt export pump deficiency after liver transplantation","volume":"361","author":"Jara","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3825","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jhep.2010.05.025","article-title":"Relapsing features of bile salt export pump deficiency after liver transplantation in two patients with progressive familial intrahepatic cholestasis type 2","volume":"53","author":"Maggiore","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3830","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/lt.23754","article-title":"Rituximab as therapy for the recurrence of bile salt export pump deficiency after liver transplantation","volume":"19","author":"Lin","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3835","first-page":"47","article-title":"Iterative antibody-induced bile salt export pump deficiency after successive liver transplantations successfully treated with plasmapheresis and rituximab","author":"Wischlen","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3840","first-page":"23","article-title":"Successful treatment with rituximab and immunoadsorption for an auto-antibody induced bile salt export pump deficiency in a liver transplanted patient","author":"Quintero","year":"2020","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3845","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/MPG.0000000000002926","article-title":"Cholestasis due to USP53 deficiency","volume":"72","author":"Bull","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3850","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ajhg.2018.01.009","article-title":"Loss-of-function mutations in UNC45A cause a syndrome associating cholestasis, diarrhea, impaired hearing, and bone fragility","volume":"102","author":"Esteve","year":"2018","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3855","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/s41436-018-0288-x","article-title":"Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants","volume":"21","author":"Maddirevula","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3860","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/ng.2918","article-title":"Mutations in TJP2 cause progressive cholestatic liver disease","volume":"46","author":"Sambrotta","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21688370.2015.1026537","article-title":"Mutations in TJP2, encoding zona occludens 2, and liver disease","volume":"3","author":"Sambrotta","year":"2015","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3870","first-page":"7","article-title":"Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis","author":"Gomez-Ospina","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3875","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/hep.27872","article-title":"Hepatocellular carcinoma associated with tight-junction protein 2 deficiency","volume":"62","author":"Zhou","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3880","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/MPG.0000000000002740","article-title":"Mutations in myosin 5B in children with early-onset cholestasis","volume":"71","author":"Cockar","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3885","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.28779","article-title":"MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease","volume":"65","author":"Gonzales","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3890","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/hep.26974","article-title":"MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillous inclusion disease","volume":"60","author":"Girard","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3895","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/adc.85.5.415","article-title":"ARC syndrome: an expanding range of phenotypes","volume":"85","author":"Eastham","year":"2001","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3900","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ng.538","article-title":"Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization","volume":"42","author":"Cullinane","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3905","first-page":"40","article-title":"Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome: from molecular genetics to clinical features","author":"Zhou","year":"2014","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3910","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/hep4.1320","article-title":"Recessive mutations in KIF12 cause high gamma-glutamyltransferase cholestasis","volume":"3","author":"\u00dcnl\u00fcsoy Aksu","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3915","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jpeds.2021.09.019","article-title":"KIF12 variants and disturbed hepatocyte polarity in children with a phenotypic spectrum of cholestatic liver disease","volume":"240","author":"Stalke","year":"2022","journal-title":"J Pediatr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3920","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/hep4.2051","article-title":"Clinical phenotype of adult-onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1","volume":"6","author":"Nayagam","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3925","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/hep.23539","article-title":"ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history","volume":"51","author":"Davit-Spraul","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3930","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2010.01.034","article-title":"Differences in presentation and progression between severe FIC1 and BSEP deficiencies","volume":"53","author":"Pawlikowska","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3935","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/hep4.2051","article-title":"Clinical phenotype of adult-onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1","volume":"6","author":"Nayagam","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3940","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jhep.2017.07.004","article-title":"Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants","volume":"67","author":"Dr\u00f6ge","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3945","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00535-017-1423-1","article-title":"Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing","volume":"53","author":"Vitale","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3950","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.3748\/wjg.v18.i44.6504","article-title":"Novel ATP8B1 mutation in an adult male with progressive familial intrahepatic cholestasis","volume":"18","author":"Deng","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3955","series-title":"ATP8B1 deficiency","author":"Bull","year":"1993"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3960","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/hep4.2051","article-title":"Clinical phenotype of adult-onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1","volume":"6","author":"Nayagam","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3965","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2019.01.036","article-title":"Clinical utility of genomic analysis in adults with idiopathic liver disease","volume":"70","author":"Hakim","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3970","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.gastro.2008.03.044","article-title":"ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults","volume":"135","author":"Ziol","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3975","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00428-012-1202-6","article-title":"Aspects of liver pathology in adult patients with MDR3\/ABCB4 gene mutations","volume":"460","author":"Wendum","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3980","first-page":"5","article-title":"Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy","author":"Gonzales","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3985","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clinre.2010.11.011","article-title":"Liver diseases unique to pregnancy: a 2010 update","volume":"35","author":"Bacq","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3990","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/hep.21500","article-title":"Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy","volume":"45","author":"Schneider","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib3995","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s10354-008-0592-1","article-title":"Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases","volume":"158","author":"Trauner","year":"2008","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4000","first-page":"2","article-title":"Low phospholipid associated cholelithiasis: association with mutation in the MDR3\/ABCB4 gene","author":"Rosmorduc","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/hep4.1149","article-title":"Phenotypic spectrum and diagnostic pitfalls of ABCB4 deficiency depending on age of onset","volume":"2","author":"Schatz","year":"2018","journal-title":"Hepatol Commun"},{"issue":"Suppl 1.","key":"10.1016\/j.gastrohep.2025.502629_bib4010","article-title":"Progressive familial intrahepatic cholestasis","volume":"36","author":"Jacquemin","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/s-0030-1253223","article-title":"The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects","volume":"30","author":"Davit-Spraul","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jhep.2012.01.025","article-title":"ABCB4\/MDR3 gene mutations and cholangiocarcinomas","volume":"57","author":"Tougeron","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4025","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1111\/liv.14662","article-title":"Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma","volume":"40","author":"de Vries","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4030","first-page":"3","article-title":"Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities","author":"Dong","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4035","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/hep.510250303","article-title":"Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis","volume":"25","author":"Jacquemin","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4040","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/hep4.1149","article-title":"Phenotypic spectrum and diagnostic pitfalls of ABCB4 deficiency depending on age of onset","volume":"2","author":"Schatz","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/apt.17761","article-title":"Obeticholic acid as a second-line treatment for low phospholipid-associated cholelithiasis syndrome","volume":"59","author":"Soret","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4050","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/hep.22431","article-title":"The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor","volume":"48","author":"Frankenberg","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1089-3261(03)00133-8","article-title":"Benign recurrent intrahepatic cholestasis","volume":"8","author":"Luketic","year":"2004","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4060","first-page":"12","article-title":"Clinicopathologic features, genetics, treatment, and long-term outcomes in Japanese children and young adults with benign recurrent intrahepatic cholestasis: a multicenter study","author":"Kato","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/ng.2918","article-title":"Mutations in TJP2 cause progressive cholestatic liver disease","volume":"46","author":"Sambrotta","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4070","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00535-017-1423-1","article-title":"Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing","volume":"53","author":"Vitale","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejogrb.2015.03.020","article-title":"Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy","volume":"189","author":"Geenes","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4080","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/1471-0528.16669","article-title":"Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study","volume":"128","author":"Mitchell","year":"2021","journal-title":"BJOG"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0301-2115(98)00086-4","article-title":"Relevance of serum bile acid profile in the diagnosis of intrahepatic cholestasis of pregnancy in an high incidence area: Portugal","volume":"80","author":"Brites","year":"1998","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4090","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/archderm.143.6.757","article-title":"The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from central Europe","volume":"143","author":"Ambros-Rudolph","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4095","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00404-020-05456-y","article-title":"Intrahepatic cholestasis of pregnancy as a risk factor for preeclampsia","volume":"301","author":"Mor","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejogrb.2017.09.012","article-title":"A retrospective cohort review of intrahepatic cholestasis of pregnancy in a South Australian population","volume":"218","author":"Marathe","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4105","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0140-6736(18)31877-4","article-title":"Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses","volume":"393","author":"Ovadia","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4110","doi-asserted-by":"crossref","first-page":"8566","DOI":"10.1080\/14767058.2021.1988924","article-title":"Intrahepatic cholestasis of pregnancy: risk factors for severe disease","volume":"35","author":"Mashburn","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jhep.2020.11.038","article-title":"Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations","volume":"74","author":"Vasavan","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4120","first-page":"46","article-title":"Effects of elevated bile acid levels on fetal myocardium in intrahepatic cholestasis of pregnancy, a retrospective study from a neonatal perspective","author":"Wang","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4125","first-page":"15","article-title":"Perinatal outcomes of intrahepatic cholestasis during pregnancy: an 8-year case-control study","author":"Arthuis","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4130","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1080\/07853890.2022.2136400","article-title":"Prevalence, risk factors and adverse perinatal outcomes for Chinese women with intrahepatic cholestasis of pregnancy: a large cross-sectional retrospective study","volume":"54","author":"Wu","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4135","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1053\/j.gastro.2012.08.004","article-title":"Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis","volume":"143","author":"Bacq","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/hep.1840040217","article-title":"Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration","volume":"4","author":"Frezza","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4145","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1053\/j.gastro.2005.06.019","article-title":"Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy","volume":"129","author":"Kondrackiene","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4150","first-page":"21","author":"Hague","year":"2021","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4155","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/hep.20952","article-title":"Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid","volume":"42","author":"Glantz","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4160","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2468-1253(21)00074-1","article-title":"Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis","volume":"6","author":"Ovadia","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4165","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1080\/14767058.2019.1685965","article-title":"Perinatal death by bile acid levels in intrahepatic cholestasis of pregnancy: a systematic review","volume":"34","author":"Di Mascio","year":"2021","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4170","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/hep.26617","article-title":"Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study","volume":"59","author":"Geenes","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4175","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1111\/1471-0528.17206","article-title":"Intrahepatic cholestasis of pregnancy","volume":"129","author":"Girling","year":"2022","journal-title":"BJOG"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4180","first-page":"374","article-title":"Hormonal contraception after intrahepatic cholestasis of pregnancy","volume":"76","author":"Kasc\u00e1k","year":"2011","journal-title":"Ceska Gynekol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4185","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1080\/14767058.2021.1925645","article-title":"Predictive factors associated with disease recurrence in patients with severe intrahepatic cholestasis of pregnancy: a retrospective study of 118 cases","volume":"35","author":"Wang","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4190","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cld.2022.06.009","article-title":"Evaluation and management of pruritus in primary biliary cholangitis","volume":"26","author":"D\u00fcll","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4195","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1053\/j.gastro.2005.06.019","article-title":"Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy","volume":"129","author":"Kondrackiene","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1081-1206(10)63385-6","article-title":"Prospective controlled study of hydroxyzine and cetirizine in pregnancy","volume":"78","author":"Einarson","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4205","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1155\/2008\/969826","article-title":"Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports","volume":"22","author":"Alallam","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0041-1729972","article-title":"Drug-induced vanishing bile duct syndrome: from pathogenesis to diagnosis and therapeutics","volume":"41","author":"Bessone","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4215","first-page":"1161","article-title":"Histopathological features predicting long-term clinical outcomes in patients with vanishing bile duct syndrome","volume":"11","author":"Lv","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4220","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/hep.28967","article-title":"Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements","volume":"65","author":"Bonkovsky","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4225","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.3748\/wjg.v12.i22.3487","article-title":"Ursodeoxycholic acid treatment of vanishing bile duct syndromes","volume":"12","author":"Pusl","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4230","unstructured":"Karageorgos SA, Tzardi M, Stratakou S, Voumvouraki A, Notas G, Kouroumalis E. Favourable long term effect of ursodeoxycholic acid treatment on congenital vanishing bile duct syndromes. Acta Gastroenterol Belg. 2018;81:330-332."},{"key":"10.1016\/j.gastrohep.2025.502629_bib4235","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00774-007-0833-1","article-title":"Primary biliary cirrhosis and osteoporosis: a case-control study","volume":"26","author":"Mounach","year":"2008","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4240","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2004.11.035","article-title":"Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis","volume":"42","author":"Gua\u00f1abens","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4245","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/MEG.0000000000001791","article-title":"Relationship between osteoporosis, sarcopenia, vertebral fracture, and osteosarcopenia in patients with primary biliary cholangitis","volume":"33","author":"Saeki","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4250","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/jgh.13746","article-title":"Risk of secondary osteoporosis due to lobular cholestasis in non-cirrhotic primary biliary cholangitis","volume":"32","author":"Seki","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4255","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1053\/j.gastro.2010.02.016","article-title":"Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis","volume":"138","author":"Gua\u00f1abens","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4260","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0016-5085(88)80029-5","article-title":"Fat-soluble vitamin nutriture in primary biliary cirrhosis","volume":"95","author":"Kaplan","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4265","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1111\/j.1572-0241.2001.04134.x","article-title":"Fat-soluble vitamin levels in patients with primary biliary cirrhosis","volume":"96","author":"Phillips","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4270","first-page":"15","article-title":"Prognostic significance of severe vitamin d deficiency in patients with primary sclerosing cholangitis","author":"Ebadi","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/ajcn\/52.2.383","article-title":"deficiency and psychomotor dysfunction in adults with primary biliary cirrhosis","volume":"52","author":"Arria","year":"1990","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4280","first-page":"13","article-title":"The role of vitamin K in cholestatic liver disease","author":"Sultana","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4285","first-page":"2059","article-title":"Plasma vitamin K1 level is decreased in primary biliary cirrhosis","volume":"92","author":"Kowdley","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502629_bib4290","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2036.2000.00729.x","article-title":"Plasma antioxidant levels in chronic cholestatic liver diseases","volume":"14","author":"Floreani","year":"2000","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525004996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525004996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:32:03Z","timestamp":1775129523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570525004996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":659,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0210570525004996"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502629","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spanish clinical practice guidelines for the diagnosis and management of cholestatic liver diseases in adult and pediatric population: Joint report from AEEH and SEGHNP","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502629"}}